90 related articles for article (PubMed ID: 8345033)
21. Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study.
Lossl K; Loft A; Freiesleben NL; Bangsbøll S; Andersen CY; Pedersen AT; Hartwell D; Andersen AN
Eur J Obstet Gynecol Reprod Biol; 2009 May; 144(1):48-53. PubMed ID: 19261371
[TBL] [Abstract][Full Text] [Related]
22. Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists.
Bedaiwy MA; Mousa NA; Casper RF
Fertil Steril; 2009 Apr; 91(4 Suppl):1574-7. PubMed ID: 18973892
[TBL] [Abstract][Full Text] [Related]
23. Comparison of two aromatase inhibitors in women with clomiphene-resistant polycystic ovary syndrome.
Al-Omari WR; Sulaiman WR; Al-Hadithi N
Int J Gynaecol Obstet; 2004 Jun; 85(3):289-91. PubMed ID: 15145273
[No Abstract] [Full Text] [Related]
24. [Aromatase inhibitors: pharmacological aspects].
de Crémoux P
Bull Cancer; 2000 Dec; 87 Spec No():23-29. PubMed ID: 11250605
[TBL] [Abstract][Full Text] [Related]
25. [Preclinical evaluation of aromatase inhibitors antitumor activity].
Auvray P; Bichat F; Genne P
Bull Cancer; 2000 Dec; 87 Spec No():7-22. PubMed ID: 11250604
[TBL] [Abstract][Full Text] [Related]
26. [Neoadjuvant use of the aromatase inhibitor letrozole in uterine cancer: endocrine and clinical effects].
Bershteĭn LM; Maksimov SIa; Gershfel'd ED; Gamaiunova VB; Tsyrlina EV; Meshkova IE; Kovalenko IG; Larionov AA; Kovalevskiĭ AIu; Vasil'ev DA
Vopr Onkol; 2001; 47(5):571-4. PubMed ID: 11785098
[TBL] [Abstract][Full Text] [Related]
27. A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors.
Schech A; Yu S; Goloubeva O; McLenithan J; Sabnis G
Endocr Relat Cancer; 2015 Aug; 22(4):645-56. PubMed ID: 26113604
[TBL] [Abstract][Full Text] [Related]
28. Endogenous estrogens influence endothelial function in young men.
Lew R; Komesaroff P; Williams M; Dawood T; Sudhir K
Circ Res; 2003 Nov; 93(11):1127-33. PubMed ID: 14592997
[TBL] [Abstract][Full Text] [Related]
29. Stimulation of Sertoli cell proliferation: defining the response interval to an inhibitor of estrogen synthesis in the boar.
Berger T; Kentfield L; Roser JF; Conley A
Reproduction; 2012 Apr; 143(4):523-9. PubMed ID: 22367591
[TBL] [Abstract][Full Text] [Related]
30. Gonadotropins stimulate growth of MCF-7 human breast cancer cells by promoting intracellular conversion of adrenal androgens to estrogens.
Tanaka Y; Kuwabara K; Okazaki T; Fujita T; Oizumi I; Kaiho S; Ogata E
Oncology; 2000; 59 Suppl 1():19-23. PubMed ID: 11096352
[TBL] [Abstract][Full Text] [Related]
31. Aromatase inhibitors prevent spontaneous granular cell tumors in the distal female reproductive tract of Sprague-Dawley rats.
Markovits JE; Sahota PS
Toxicol Pathol; 2000; 28(6):799-801. PubMed ID: 11127293
[TBL] [Abstract][Full Text] [Related]
32. Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
Ingle JN
Steroids; 2011 Jul; 76(8):765-7. PubMed ID: 21382394
[TBL] [Abstract][Full Text] [Related]
33. Aromatase inhibition: translation into a successful therapeutic approach.
Geisler J; Lønning PE
Clin Cancer Res; 2005 Apr; 11(8):2809-21. PubMed ID: 15837728
[TBL] [Abstract][Full Text] [Related]
34. Role for endogenous estrogen in prepubertal Sertoli cell maturation.
Kao E; Villalon R; Ribeiro S; Berger T
Anim Reprod Sci; 2012 Nov; 135(1-4):106-12. PubMed ID: 23041111
[TBL] [Abstract][Full Text] [Related]
35. Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
Hamilton A; Volm M
Oncology (Williston Park); 2001 Aug; 15(8):965-72; discussion 972, 977-9. PubMed ID: 11548977
[TBL] [Abstract][Full Text] [Related]
36. Aromatase inhibitors in recurrent ovarian endometriomas: report of five cases with literature review.
Lall Seal S; Kamilya G; Mukherji J; De A; Ghosh D; Majhi AK
Fertil Steril; 2011 Jan; 95(1):291.e15-8. PubMed ID: 20579642
[TBL] [Abstract][Full Text] [Related]
37. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
[TBL] [Abstract][Full Text] [Related]
38. Endocrine changes, fetal growth, and uterine artery hemodynamics after chronic estrogen suppression during the last trimester of equine pregnancy.
Esteller-Vico A; Ball BA; Troedsson MHT; Squires EL
Biol Reprod; 2017 Feb; 96(2):414-423. PubMed ID: 28203724
[TBL] [Abstract][Full Text] [Related]
39. The effects of Nobiletin, Hesperetin, and Letrozole in a combination on the activity and expression of aromatase in breast cancer cells.
Rahideh ST; Keramatipour M; Nourbakhsh M; Koohdani F; Hoseini M; Shidfar F
Cell Mol Biol (Noisy-le-grand); 2017 Feb; 63(2):9-13. PubMed ID: 28364779
[TBL] [Abstract][Full Text] [Related]
40. Letrozole. A review of its use in postmenopausal women with advanced breast cancer.
Lamb HM; Adkins JC
Drugs; 1998 Dec; 56(6):1125-40. PubMed ID: 9878997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
